老虎證券

Dwindling COVID-19 Test Demand Forces LumiraDx Cut SPAC Deal Value

Benzinga
2021/08/21
  • Fall in demand for COVID-19 screening has led LumiraDx to slash $2 billion off the value of a planned reverse merger with a special purpose acquisition company (SPAC).
  • See: LumiraDx Withdraws $100M IPO In Favor Of $5B SPAC Merger. 
  • First announced in April, the U.K.-based diagnostics company aimed to debut on NASDAQ with the blank-check firm CA Healthcare Acquisition Corp (NASDAQ:CAHC) and had charted out a $5 billion pro forma enterprise value for the combination.
  • Now LumiraDx is knocking 40% off that projected valuation while also saying that the market environment for publicly traded diagnostic companies has changed and is following feedback from the SPAC’s advisors and shareholders.
  • LumiraDx also reduced its revenue guidance for 2021, from the $600 million to $1 billion it had been forecasting in April, down to $300 million to $500 million by the end of this year.
  • Related: LumiraDX COVID-19 Antibody Test Received FDA Emergency Use Nod.
  • Price Action: CAHC shares are up 0.29% at $9.90 during the market session on the last check Friday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10